Potential Benefits of Bevacizumab Combined With Platinum-Based Chemotherapy in Advanced Non–Small-Cell Lung Cancer Patients With EGFR Mutation

Ichidai Tanaka, Masahiro Morise, Ayako Miyazawa, Yuta Kodama, Yutaro Tamiya, Soei Gen, Akira Matsui, Tetsunari Hase, Naozumi Hashimoto, Mitsuo Sato, Yoshinori Hasegawa

Research output: Contribution to journalArticlepeer-review

22 Citations (Scopus)

Abstract

To investigate the clinical benefits of bevacizumab plus cytotoxic chemotherapy in lung cancer patients with EGFR mutation, we retrospectively assessed clinical data of 159 subjects. The use of the standard chemotherapy with bevacizumab provided better clinical benefit to patients with EGFR mutation than wild-type carriers.

Original languageEnglish
Pages (from-to)273-280.e4
JournalClinical Lung Cancer
Volume21
Issue number3
DOIs
Publication statusPublished - 05-2020
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Fingerprint

Dive into the research topics of 'Potential Benefits of Bevacizumab Combined With Platinum-Based Chemotherapy in Advanced Non–Small-Cell Lung Cancer Patients With EGFR Mutation'. Together they form a unique fingerprint.

Cite this